

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


# **Single Technology Appraisal**

# Efgartigimod with recombinant human hyaluronidase PH20 for treating chronic inflammatory demyelinating polyneuropathy ID6409

# **Provisional Stakeholder List**

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	
<ul> <li>Company</li> <li>Argenx (efgartigimod with recombinant human hyaluronidase PH20)</li> <li>Patient/carer groups</li> <li>Brain and Spine Foundation</li> <li>Brain Charity</li> <li>Guillain-Barré and Associated Inflammatory Neuropathies (GAIN)</li> <li>Neurological Alliance</li> <li>South Asian Health Foundation</li> <li>Specialised Healthcare Alliance</li> <li>Healthcare professional groups</li> <li>Association of British Neurologists</li> <li>British Geriatrics Society</li> <li>British Neuropathological Society</li> <li>National Neurosciences Advisory Group</li> <li>Primary Care and Community Neurology Society</li> </ul>	<ul> <li>General</li> <li>All Wales Therapeutics and Toxicology Centre</li> <li>Allied Health Professionals Federation</li> <li>Board of Community Health Councils in Wales</li> <li>British National Formulary</li> <li>Care Quality Commission</li> <li>Department of Health - Northern Ireland</li> <li>Healthcare Improvement Scotland</li> <li>Medicines and Healthcare products Regulatory Agency</li> <li>National Association of Primary Care</li> <li>National Pharmacy Association</li> <li>Neurological Alliance of Scotland</li> <li>NHS Confederation</li> <li>Scottish Medicines Consortium</li> <li>Wales Neurological Alliance</li> <li>Welsh Government</li> <li>Welsh Health Specialised Services</li> </ul>
<ul> <li>Royal College of General Practitioners</li> <li>Royal College of Nursing</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> <li>UK Clinical Pharmacy Association</li> </ul> Others <ul> <li>Department of Health and Social Care</li> <li>NHS England</li> </ul>	Possible comparator companies

Provisional stakeholder list for the evaluation of efgartigimod with recombinant human hyaluronidase PH20 for treating chronic inflammatory demyelinating polyneuropathy ID6409 Issue date: November 2024




Provisional Consultees	Provisional Commentators (no right to submit or appeal)
	<ul> <li>Morningside Healthcare (methotrexate)</li> <li>Mylan (azathioprine, ciclosporin)</li> <li>Nordic Pharma (methotrexate)</li> <li>Nova Laboratories (azathioprine)</li> <li>Novartis (ciclosporin)</li> <li>Octapharma (human immunoglobulin)</li> <li>Orion Pharma (methotrexate)</li> <li>Pfizer (methotrexate)</li> <li>Roche (mycophenolate mofetil)</li> <li>Rosemont Pharmaceuticals (methotrexate, mycophenolate mofetil)</li> <li>Sandoz (cyclophosphamide)</li> <li>Santen (ciclosporin)</li> <li>Takeda UK (human immunoglobulin)</li> <li>Teva Pharma (mycophenolate mofetil)</li> <li>Therakind (methotrexate)</li> <li>Tillomed Laboratories (azathioprine, mycophenolate mofetil)Strides Pharma (azathioprine)</li> </ul>
	<ul> <li>Relevant research groups</li> <li>Brain Research UK</li> <li>Genomics England</li> <li>Institute of Neurology</li> <li>MRC Clinical Trials Unit</li> <li>National Hospital for Neurology and Neurosurgery</li> <li>National Institute for Health Research</li> </ul> Associated Public Health groups <ul> <li>Public Health Wales</li> <li>UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

#### Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Provisional stakeholder list for the evaluation of efgartigimod with recombinant human hyaluronidase PH20 for treating chronic inflammatory demyelinating polyneuropathy ID6409 Issue date: November 2024



### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.